Esker, A New Biotech Startup, Launches With Plans To Make Targeted Immune Drugs
Having raised $115 million in a Series B financing round, Talaris Therapeutics is seeking to raise another $100 million through an initial public offering, after raising $125 million from private equity firm Kleiner Perkins Caufield & Byers and $30 million through a Series A round of $50 million.
The founders of the company are Peter Fedichev, who holds a Master’s degree in Capacitor Science from Bristol University and is the driving force behind the company’s scientific research, and Maxim Kholin, who holds a PhD in Biomedical Engineering from Harvard Medical School. Mayo Clinic announced Wednesday that it has created two new technology companies that use artificial intelligence (AI) medical algorithms to develop software and medical devices that doctors can use to improve the treatment of various diseases. A team of top scientists from Bristol University has announced the creation of a new biotech company to develop breakthrough, newly patented potential treatments for a range of diseases including Alzheimer’s, Parkinson’s and Alzheimer’s.
The startup team already has extensive experience with the 20 leading pharmaceutical companies such as Pfizer, Eli Lilly, Bristol-Myers Squibb, Bayer, Merck & Co. and others.
Gero currently works with a number of pharmaceutical companies including Pfizer, Eli Lilly, Bristol-Myers Squibb, Bayer, Merck & Co. Findmecure was founded in 2012 by healthcare entrepreneurs Dr Gero and his co-founder Professor Ravi Jain and is already named after him for Google Clinical Trials.
The solution removes barriers for all stakeholders and allows more people to participate in different clinical trials with less time, cost and time to market and with less risk of failure.
The aim is to support the organisation of new clinical trials with the development of research to date. Through their work on patient support and community engagement, Techstar London Accelerator graduates are committed to raising awareness of clinical trials, helping to discover a new drug and supporting proactive development in medicine. Esker’s efforts are very early, apart from ESK-001, and focus on analytical technology to support the development of multiple stages and programs of discovery.
The company’s goal is to investigate specific biomarkers and biological pathways that could improve the treatment and response to various autoimmune diseases, as well as the development of new therapies for autoimmune diseases.
Lee said that data from genetics and clinical records have not been well connected in the past, and Esker wants to correct that. Mr Hhe added: “We are starting to attract the attention of larger companies, but partnerships with these companies remain key to applying Repertoire’s technology to more diseases. Eskers wants to rectify this, Lee said, by drawing attention to large companies as potential partners for their research and development efforts.
Cox said the new funding would allow his company to work on several programs at once and would continue to fund research and development well into next year.
Unlike many cell therapy developers, Cox says the start-up does not plan to build its own production facility, but instead enters into partnerships with other companies.
Last year, Roche’s subsidiary Genentech acquired San Diego, a biotech company based in Versant Therapeutics, to gain access to a medicine for NASH, a liver disease that is not yet FDA approved. Cox said the Serie A side will support the development of the NASH drug. Another start-up, Jecure Therapies, began as a joint venture between the University of California, San Francisco, and New York University School of Medicine. Bigal says JECure is developing a therapy that targets the NLRP3 inflammasome, and that Versant led a $1.5 million Series B funding round from the U.S. Department of Veterans Affairs in 2017.
Bigal added that the agreement gives him confidence that innate immunity research will grow in the US and other parts of the world, as well as in Europe.
Ventus joins a growing group of start-ups developing drugs that target the innate immune system. Boston – IFM Therapeutics has entered into two deals with Novartis (NYSE: NVS) but will continue to independently conduct research and development of its innate immunity medicines. In November 2019, Bigal said Ventus had plans to complete a Series A financing round of $1.5 million from private equity firms.
Ceyeber has established itself as a unique, advanced human cybernetics company that has developed an emerging technology based on a strong IP portfolio. The company is seeking a partnership with Centessa Pharmaceuticals, which was launched last year after the merger of 10 private biotech companies.
The company received funding last year from Covid Research, a public-private research organization that uses computing resources to support its research. The company is funded by a $1.5 million grant from the U.S. Department of Energy’s Science Office and is a member of the National Science Foundation (NSF) of the National Institutes of Health (NIH).
“This study identified antigens and viruses that trigger a T-cell reaction, and the study was conducted on lung fluid samples taken from patients,” Cox said. In addition to presenting and publishing her research in the Journal of the American Academy of Neurology and other journals, she has begun to present and publish her findings in a number of scientific journals, including Nature, Science, Nature Biotechnology and Nature Communications.
